Mechanisms of disease: Iron overload in human disease

New England Journal of Medicine

Volumn 366, Issue 4, 2012, Pages 348-359

  Fleming, Robert E ^a   Ponka, Prem ^b,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEPCIDIN; HFE PROTEIN; IMMUNOGLOBULIN; IRON; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN;

ALPHA THALASSEMIA; APLASTIC ANEMIA; BETA THALASSEMIA; BLOOD OXYGEN TENSION; CELL DAMAGE; CHELATION THERAPY; CONGENITAL DYSERYTHROPOIETIC ANEMIA; DIVALENT METAL TRANSPORTER 1 GENE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; HEMOCHROMATOSIS; HFE GENE; HOMEOSTASIS; HUMAN; INTESTINE CELL; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LABORATORY TEST; LEARNING ALGORITHM; LIVER BIOPSY; LIVER CELL; METABOLIC REGULATION; MYELODYSPLASTIC SYNDROME; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION GENE; PHLEBOTOMY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIDEROBLASTIC ANEMIA; ABSORPTION; IRON INTAKE; IRON METABOLISM DISORDER; METABOLISM;

ABSORPTION; HEPATOCYTES; HUMANS; IRON; IRON METABOLISM DISORDERS; IRON OVERLOAD; IRON, DIETARY;

EID: 84856292277     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1004967     Document Type: Article

References (102)

1. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007; 17:93-100. (Pubitemid 46199183)
2. Simpson RJ, McKie AT. Regulation of intestinal iron absorption: the mucosa takes control? Cell Metab 2009;10:84-7.
3. Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 2009;9:152-64.
4. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2 alpha, but not HIF-1 alpha, promotes iron absorption in mice. J Clin Invest 2009;119:1159-66.
5. Galy B, Ferring-Appel D, Kaden S, Gröne HJ, Hentze MW. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell Metab 2008; 7:79-85.
6. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2 alpha expression in iron deficiency. Nat Struct Mol Biol 2007;14:420-6. (Pubitemid 46685876)
7. Zimmer M, Ebert BL, Neil C, et al. Small-molecule inhibitors of HIF-2a translation link its 5?UTR iron-responsive element to oxygen sensing. Mol Cell 2008;32:838-48.
8. Zhang DL, Hughes RM, Ollivierre- Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab 2009;9:461-73.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306: 2090-3. (Pubitemid 40007660)
10. De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci U S A 2009;106:3800-5.
11. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2011 August 9 (Epub ahead of print).
12. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87. (Pubitemid 40298370)
13. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997;89:1-25. (Pubitemid 26428173)
14. Kondo H, Saito K, Grasso JP, Aisen P. Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology 1988;8: 32-8. (Pubitemid 18092055)
15. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203. (Pubitemid 26248989)
16. De Domenico I, Vaughn MB, Paradkar PN, Lo E, Ward DM, Kaplan J. Decoupling ferritin synthesis from free cytosolic iron results in ferritin secretion. Cell Metab 2011;13:57-67.
17. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta 2010;1800:760-9.
18. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A 2005; 102:1324-8. (Pubitemid 40209169)
19. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650-69.
20. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
21. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6. (Pubitemid 39069926)
22. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008;112:1503-9.
23. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933-9. (Pubitemid 47036327)
24. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009;41:478-81.
25. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009;41:482-7.
26. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008;111:5195-204.
27. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005;2:399-409.
28. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Invest 2005;115:2187-91. (Pubitemid 41134160)
29. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005;115:2180-6. (Pubitemid 41134159)
30. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-9.
31. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008;7:205-14. (Pubitemid 351285524)
32. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006;281: 28494-8. (Pubitemid 44506991)
33. Bennett MJ, Lebrón JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature 2000;403:46-53. (Pubitemid 30038514)
34. Chen J, Chloupková M, Gao J, Chapman- Arvedson TL, Enns CA. HFE modulates transferrin receptor 2 levels in hepatoma cells via interactions that differ from transferrin receptor 1-HFE interactions. J Biol Chem 2007;282:36862-70.
35. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009;9:217-27.
36. Kautz L, Meynard D, Besson-Fournier C, et al. BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood 2009;114: 2515-20.
37. Corradini E, Garuti C, Montosi G, et al. Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology 2009;137:1489-97.
38. Poli M, Luscieti S, Gandini V, et al. Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling: implications for transferrin-dependent hepcidin regulation. Haematologica 2010;95: 1832-40.
39. Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ, Subramaniam VN. Combined deletion of HFE and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009;50:1992- 2000.
40. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101. (Pubitemid 47517510)
41. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112:5241-4.
42. Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med (Berl) 2011;89:811-6.
43. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-6.
44. Lakhal S, Schödel J, Townsend ARM, Pugh CW, Ratcliffe PJ, Mole DR. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J Biol Chem 2011; 286:4090-7.
45. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8:502-11.
46. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008;111:924-31.
47. Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 2010;12:445-58.
48. Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis- related morbidity. Hepatology 2009;50: 94-101.
49. Camaschella C, Roetto A, Calì A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5. (Pubitemid 30257027)
50. Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001;97:2555-60.
51. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36: 77-82. (Pubitemid 38056211)
52. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2. (Pubitemid 36068676)
53. Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128:470-9. (Pubitemid 40431098)
54. De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. Haematologica 2006;91:92-5. (Pubitemid 43235391)
55. Fernandes A, Preza GC, Phung Y, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009; 114:437-43.
56. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005;105:4103-5. (Pubitemid 40656161)
57. McNamara L, Gordeuk VR, MacPhail AP. Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol 2005;20:1855-8. (Pubitemid 43961041)
58. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006;91: 727-32. (Pubitemid 44014536)
59. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56.
60. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci 2010;1202:1-9.
61. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010; 16:177-82.
62. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest 2010; 120:4466-77.
63. Parrow NL, Gardenghi S, Rivella S. Prospects for a hepcidin mimic to treat beta-thalassemia and hemochromatosis. Expert Rev Hematol 2011;4:233-5.
64. Fleming MD. The genetics of inherited sideroblastic anemias. Semin Hematol 2002;39:270-81. (Pubitemid 35192640)
65. Renella R, Wood WG. The congenital dyserythropoietic anemias. Hematol Oncol Clin North Am 2009;23:283-306.
66. Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk Lymphoma 2008;49:427-38. (Pubitemid 351298326)
67. Goldwurm S, Casati C, Venturi N, et al. Biochemical and genetic defects underlying human congenital hypotransferrinemia. Hematol J 2000;1:390-8.
68. Trombini P, Coliva T, Nemeth E, et al. Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica 2007;92: 1407-10. (Pubitemid 350144159)
69. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood 2011;117:630-7.
70. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998;67:5 Suppl:972S-977S. (Pubitemid 28198819)
71. Blanco E, Kannengiesser C, Grandchamp B, Tasso M, Beaumont C. Not all DMT1 mutations lead to iron overload. Blood Cells Mol Dis 2009;43:199-201.
72. Murray KF, Kowdley KV. Neonatal hemochromatosis. Pediatrics 2001;108: 960-4. (Pubitemid 32947667)
73. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007;27:243-50. (Pubitemid 47301764)
74. Rand EB, Karpen SJ, Kelly S, et al. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 2009;155: 566-71.
75. Whitington PF, Hibbard JU. High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 2004;364:1690-8. (Pubitemid 39458145)
76. Hanchard NA, Shchelochkov OA, Roy A, et al. Deoxyguanosine kinase deficiency presenting as neonatal hemochromatosis. Mol Genet Metab 2011;103:262-7.
77. Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord 2004;19:36-42. (Pubitemid 38559618)
78. Kurian MA, McNeill A, Lin JP, Maher ER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol 2011;53: 394-404.
79. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-9. (Pubitemid 32702423)
80. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40. (Pubitemid 36026344)
81. Curtis ARJ, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-4. (Pubitemid 32702424)
82. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006; 13:142-8. (Pubitemid 44709651)
83. Barnham KJ, Bush AI. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 2008;12:222-8.
84. Becker E, Richardson DR. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol 2001;33:1-10. (Pubitemid 32146462)
85. Richardson DR, Lane DJ, Becker EM, et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A 2010;107:10775-82.
86. Puccio H, Simon D, Cossée M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001;27:181-6. (Pubitemid 32157445)
87. Herbert V. Hemochromatosis and vitamin C. Ann Intern Med 1999;131:475-6.
88. Mainous AG III, Diaz VA, Everett CJ, et al. IRon overload screeNing tool (IRON): development of a tool to guide screening in primary care. Am J Hematol 2011;86: 733-7.
89. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary carebased adults. Am J Med Sci 2003;325:53-62. (Pubitemid 36236661)
90. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev 2009;23:95-104.
91. Camaschella C, Poggiali E. Towards explaining "unexplained hyperferritinemia." Haematologica 2009;94:307-9.
92. Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001;69:191-7. (Pubitemid 32614030)
93. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol 2011;152:512-23.
94. van Bokhoven MA, van Deursen CT, Swinkels DW. Diagnosis and management of hereditary haemochromatosis. BMJ 2011;342:c7251.
95. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-62. (Pubitemid 29283985)
96. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009;33:Suppl 1: S46-S47.
97. Valberg LS, Ludwig J, Olatunbosun D. Alteration in cobalt absorption in patients with disorders of iron metabolism. Gastroenterology 1969;56:241-51.
98. Altstatt LB, Pollack S, Feldman MH, Reba RC, Crosby WH. Liver manganese in hemochromatosis. Proc Soc Exp Biol Med 1967;124:353-5.
99. Barton JC, Patton MA, Edwards CQ, et al. Blood lead concentrations in hereditary hemochromatosis. J Lab Clin Med 1994;124:193-8. (Pubitemid 2134311)
100. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin- containing organs. Blood 2005; 106:2196-9. (Pubitemid 41291740)
101. Breda L, Gardenghi S, Guy E, et al. Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia. Ann N Y Acad Sci 2005;1054:417-22. (Pubitemid 43031049)
102. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 2011;54:173-81.